Market Trends of Cell And Gene Therapy Contract Development And Manufacturing Organization Industry
Neurological Disorders Segment is Expected to Hold a Significant Share Over the Forecast Period
Cell and gene therapy CDMO plays a crucial role in advancing therapies for neurological diseases through their specialized services. CDMOs often have specialized knowledge and expertise in cell and gene therapy, which is particularly important in the complex field of neurological treatments. They typically have advanced manufacturing facilities equipped with the necessary technology and infrastructure to handle the specific requirements of cell and gene therapies for neurological conditions.
The rising burden of neurological diseases is one of the key factors for increasing demand for cell and gene therapeutics and, thus, for CDMO, as the development and manufacturing of cell and gene therapy is complex and requires expertise. For instance, according to the World Health Organisation's data updated in February 2022, around 50 million people worldwide suffer from epilepsy every year. Further, according to the World Alzheimer's Report of 2023, an estimated 6.7 million Americans aged 65 and older will be living with Alzheimer’s dementia in 2023, and this is expected to increase to 13.8 million by 2060. Thus, the growing burden of neurological diseases will likely contribute to the segment growth.
Further, market players in cell and gene therapy CDMO services are utilizing various strategies such as expansion of services, mergers, acquisitions, and agreements to improve their market position. For instance, in June 2023, the New Hope Research Foundation and Forges Biologics, a CDMO, announced a development and cGMP manufacturing partnership to advance the Foundation’s novel gene therapy, NHR01, into Phase I/II clinical trials for patients with GM2 gangliosidosis. Similarly, in September 2022, Charles River Laboratories International, Inc. and Cure AP-4 announced a manufacturing collaboration to provide High Quality (HQ) plasmid DNA for Cure AP-4’s Phase I/II gene therapy trials against Adapter-Protein 4 Hereditary Spastic Paraplegia (AP-4 HSP).
Hence, the growing burden of neurological diseases and strategic activities by the market players is expected to boost the segment growth over the forecast period.
North America is Expected to Hold a Significant Market Share Over the Forecast Period
In North America, the cell and gene therapy CDMO market is expected to grow owing to factors such as established research facilities, high investment in R&D for cell and gene therapy, and the growing burden of chronic diseases.
According to the data from the American Cancer Society in 2023, it is estimated that about 13% or 1 in 8 women in the United States are expected to develop invasive breast cancer during their lives. Hence, the high incidence of cancer in the nation is predicted to raise the need for novel cell and gene therapy, which would ultimately lead to a growth in R&D activities and CDMO services for the development of new drugs, thereby boosting the market growth over the forecast period.
Moreover, the increase in research and development activities and the presence of favorable healthcare infrastructure are fueling the growth of the overall regional market to a large extent. For instance, in March 2023, Remedium Bio and Biovian Oy collaborated to work together on the development of Remedium's innovative disease-modifying AAV gene therapy for Osteoarthritis. This agreement aims to advance the research and production of groundbreaking therapy, potentially offering new treatment options for patients with Osteoarthritis. Additionally, in November 2022, Charles River Laboratories International, Inc. expanded its cell therapy CDMO facility in Memphis, United States. The expanded space is suitable for clinical and commercial cell therapy manufacturing. This increase in the growth of the CDMO sector facilitates the increasing cell and gene therapy manufacturing services, thereby propelling the growth of the market.
Thus, the factors mentioned above, such as the increasing prevalence of cancer and the development by various companies, are expected to drive the growth of the market in this region.
Cell And Gene Therapy Contract Development And Manufacturing Organization Market Report Snapshots
- Cell And Gene Therapy Contract Development And Manufacturing Organization Market Size
- Cell And Gene Therapy Contract Development And Manufacturing Organization Market Share
- Cell And Gene Therapy Contract Development And Manufacturing Organization Market Trends
- Cell And Gene Therapy Contract Development And Manufacturing Organization Companies
